Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising

Allergan receives FDA’s RTF letter for Vraylar sNDA to treat schizophrenia

pharmaceufical-technologySeptember 27, 2017

Tag: Allergan , sNDA , schizophrenia

PharmaSources Customer Service